Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts - PubMed (original) (raw)
. 1990 Dec 15;50(24):8017-22.
Affiliations
- PMID: 2253244
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts
S H Bigner et al. Cancer Res. 1990.
Abstract
Both permanent cultured cell lines and athymic mouse xenografts were established from two human glioblastomas. Biopsies from D-245 MG and D-270 MG contained amplified and rearranged epidermal growth factor receptor (EGFR) genes. Although the gene amplification and rearrangement seen originally was maintained in the xenografts, cultured cell lines established from these biopsies lost the amplified rearranged genes in vitro. Analysis of these cell lines and 11 additional permanent human glioma cell lines with normal EGFR gene copy number showed from 2.7 x 10(3) to 4.1 x 10(5) high affinity EGFRs/cell by radioreceptor assay. The RNase A protection assay showed minimal differences in the quantity of EGFR mRNA among the 13 glioma lines, while the D-245 MG and D-270 MG xenografts expressed approximately 10-20 times as much EGFR mRNA as the corresponding cell lines. Immunoprecipitation of EGFR from these lines, including D-245 MG and D-270 MG, demonstrated only the intact Mr 170,000 Da form, while truncated Mr 145,000 Da and 100,000 Da EGFR proteins were immunoprecipitated from the D-270 MG and D-245 MG xenografts, respectively. These studies demonstrate that gliomas with amplification of the EGFR gene are capable of establishing in culture but that the amplified rearranged genes are not maintained. Possible explanations are that the abnormal genes are lost during serial passage or that the cells with amplified rearranged genes only represent a minor subpopulation of cells, which are unable to grow in culture. In either case, these observations suggest that high expression and structural abnormalities of EGFR proteins generated by amplification and rearrangement of the EGFR gene provide a growth advantage for gliomas in vivo but not in vitro.
Similar articles
- Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH. Humphrey PA, et al. Cancer Res. 1988 Apr 15;48(8):2231-8. Cancer Res. 1988. PMID: 3258189 - Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Ekstrand AJ, et al. Cancer Res. 1991 Apr 15;51(8):2164-72. Cancer Res. 1991. PMID: 2009534 - Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.
Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Bigner SH, et al. Cancer Res. 1990 Apr 15;50(8):2347-50. Cancer Res. 1990. PMID: 2180567 - Amplified genes in human gliomas.
Collins VP. Collins VP. Semin Cancer Biol. 1993 Feb;4(1):27-32. Semin Cancer Biol. 1993. PMID: 8448375 Review. - DNA content and chromosomal composition of malignant human gliomas.
Bigner SH, Bjerkvig R, Laerum OD. Bigner SH, et al. Neurol Clin. 1985 Nov;3(4):769-84. Neurol Clin. 1985. PMID: 3001489 Review.
Cited by
- Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario.
Bianconi A, Palmieri G, Aruta G, Monticelli M, Zeppa P, Tartara F, Melcarne A, Garbossa D, Cofano F. Bianconi A, et al. Biomedicines. 2023 May 24;11(6):1520. doi: 10.3390/biomedicines11061520. Biomedicines. 2023. PMID: 37371615 Free PMC article. Review. - Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.
Abbott RC, Iliopoulos M, Watson KA, Arcucci V, Go M, Hughes-Parry HE, Smith P, Call MJ, Cross RS, Jenkins MR. Abbott RC, et al. Clin Transl Immunology. 2023 Mar 5;12(3):e1440. doi: 10.1002/cti2.1440. eCollection 2023. Clin Transl Immunology. 2023. PMID: 36890859 Free PMC article. - Advances in NK cell therapy for brain tumors.
Fares J, Davis ZB, Rechberger JS, Toll SA, Schwartz JD, Daniels DJ, Miller JS, Khatua S. Fares J, et al. NPJ Precis Oncol. 2023 Feb 15;7(1):17. doi: 10.1038/s41698-023-00356-1. NPJ Precis Oncol. 2023. PMID: 36792722 Free PMC article. Review. - Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Morimoto T, et al. Int J Mol Sci. 2023 Jan 20;24(3):2111. doi: 10.3390/ijms24032111. Int J Mol Sci. 2023. PMID: 36768432 Free PMC article. Review. - Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
Li H, Song W, Li Z, Zhang M. Li H, et al. Front Immunol. 2022 Oct 24;13:992232. doi: 10.3389/fimmu.2022.992232. eCollection 2022. Front Immunol. 2022. PMID: 36353643 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous